Target intelligence / Profile preview

Dystrophin Exon 51

Molecular classification
Exon, Non-coding sequence, Therapeutic target site
01

Overview

Exon 51 is one of 79 exons in the *DMD* gene, which encodes the protein dystrophin. Mutations resulting in loss of the normal reading frame at or near exon 51 cause Duchenne muscular dystrophy (DMD), a severe, progressive muscle-wasting disease. Exon skipping therapy—most notably with eteplirsen—uses synthetic antisense oligonucleotides to bind pre-mRNA and induce the exclusion (skipping) of exon 51 during mRNA processing. This restores the reading frame in selected patients, enabling production of a truncated but functional dystrophin protein, often resulting in a less severe Becker muscular dystrophy–like phenotype. Exon 51 itself is not a functional molecule or protein but represents a locus for gene-editing or RNA-splicing based interventions.

Other names
Exon 51 of the DMD geneDMD exon 51Dystrophin exon 51
02

Mechanism of action

Antisense-mediated exon skipping — antisense oligonucleotides (AONs) bind to pre-mRNA at exon 51 to alter splicing, excising exon 51, restoring the reading frame, and permitting the expression of truncated but functional dystrophin protein

03

Biological functions

Pre-mRNA splicing regulation (targeted in exon skipping strategies)Indirectly involved in Skeletal muscle maintenance due to its role in dystrophin mRNA integrity
04

Disease associations

Muscle diseaseDuchenne muscular dystrophy (DMD)Becker muscular dystrophy (BMD)
05

Safety considerations

Incomplete restoration of dystrophin expressionVariability in responseHigh treatment costUncertainty about long-term clinical benefitsPotential renal toxicity (class effect of antisense oligonucleotide therapies)Infusion-related reactions (class effect of antisense oligonucleotide therapies)
06

Interacting drugs

Eteplirsen (Exondys 51)

2 more in the full profile.

07

Biomarkers

Presence of DMD gene mutations amenable to exon 51 skipping (genotyping of DMD patients for candidate eligibility)Dystrophin protein levels in muscle tissue as a pharmacodynamic biomarker

Beyond the preview

Go deeper on Dystrophin Exon 51.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dystrophin Exon 51.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call